This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03391466
Recruitment Status : Active, not recruiting
First Posted : January 5, 2018
Last Update Posted : July 6, 2023
Information provided by (Responsible Party):
Gilead Sciences ( Kite, A Gilead Company )

Results Submitted - Quality Control (QC) Review Has Not Concluded
Results information for an applicable clinical trial (ACT) is posted within 30 days of submission even if the submission has not completed the Results Quality Control (QC) review process. Results information is submitted to by the sponsor or investigator, and National Library of Medicine (NLM) staff assess for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

All versions of ACT results information submissions that have not completed the QC review process are posted on (since January 2020). After the QC review process is completed, the results information is posted without QC review comments and previous versions are archived.

Recruitment Status : Active, not recruiting
Actual Primary Completion Date : January 25, 2023
Estimated Study Completion Date : January 2035
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 December 20, 2023
January 16, 2024 Submission with QC Comments
2 February 9, 2024
Publications automatically indexed to this study by Identifier (NCT Number):